Shanghai, China, 5 March 2015 - Fresenius Medical Care, the world’s leading renal company, today announced the establishment of the China Design Center for its Global Research & Development (GRD) division. Located in Caohejing Hi-Tech Park in the Minhang District in Shanghai, the new Center heralds an important step towards consolidating the company’s position as the global leader in dialysis products and services while improving the survival rates and living standards of millions of renal patients in China and the Asia Pacific region.
The plans for the China Design Center were commemorated today in Shanghai with a signing ceremony that included key members of Fresenius Medical Care, representatives of the Caohejing Hi-Tech Park as well as officers of the Minhang District Administration.
The new facility will interface with the GRD division and link with Procurement, local Global Manufacuring Organization (GMO) facilities as well as Sales and Marketing teams to combine the vast experience and core know-how of the company’s existing German team to develop a deeper insight into the needs of the Chinese and other emerging markets. To meet these demands, additional employees will be recruited in Germany and China.
Moreover, the Center’s location in The Caohejing Hi-Tech Park in Shanghai offers the company the unique advantage of not only being connected to key academia in relevant universities but also access to infrastructure and highly trained local talent.
"This new Center is an important step to strengthen our presence in the high-growth dialysis markets of the emerging market nations and, thus, our position as the global leader in dialysis products and services,” said Dr. Olaf Schermeier, Fresenius Medical Care’s Chief Executive Officer for Global Research and Development. “Consolidating our collective knowledge and expertise will increase innovation and enhance our ability to provide cost-effective products that achieve the highest medical standards for the growing patient base in the region.”
Mr. Zhao Zhuping, Governer of the Minhang District, stated: ” We have high expectations for Fresenius medical care, and are confident that it will make meaningful contributions in the field of Chinese health care in the near future. Today, I would like to pledge Caohejing’s support of Fresenius’ ventures in China. We want to be more than just a landlord, but also a partner and friend.”
Signing Ceremony Participant Names and Titles:
- Minhang District: Zhao Zhuping (Head of District), Lin Yi (Financial and Economic Committee Director), Wang Wei (Secretary to Head), Wu Tao (Commercial and Business Development)
- Shanghai Caohejing Hi-Tech Park Development Corp.: Gui Enliang (General Manager), Lv Ming (Deputy General Manager), Richard Shen (Managing Director Marketing & Business), Cindy Cai (Senior Manager Business Development)
- Fresenius Medical Care, Global Research and Development: Olaf Schermeier (CEO), Kirill Koulechov (SVP Product Engineering Center Cost Optimized Machines), Gene Ma (VP Product Engineering Center Solutions, Concentrates, Containers), Gail-Suzanne Brown (SVP Global Therapy Programme Acute), Kai-Uwe Ritter (SVP Global Therapy Program In Center), Echo Qiao (Manager Human Resources, GRD).
About fresenius medical care:
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.7 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
For more information visit the Company’s website at www.freseniusmedicalcare.com.
Ms. Eonjung Lim
Fresenius Medical Care
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.